High-Dose Intravenous Iron Replacement Therapy for Iron Deficiency Anemia Does Not Hinder Drug-Induced Amelioration of Disease Activity in IBD Patients

    Stein Jìrgen, Stefan Vollmer, W Klemm … Dignass Axel
    Studysummary This study observed that intravenous ferric carboxymaltose did not inhibit the drug-induced reduction of inflammatory activity in patients with inflammatory bowel disease, as indicated by lower CRP levels.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on journals.lww.com →
    Discuss this study in the Community →